This study compared different CAR T cell designs and found that using a CD8α spacer and tumor necrosis factor receptor (TNFR)-based costimulation (4-1BB or CD27) enhanced the treatment’s efficacy. It improved CAR expression stability, reduced self-targeting of T cells, and ensured prolonged tumor-killing activity. TIM3 was confirmed as a safe and effective target with minimal side effects on healthy cells.
Funding
This research project is supported by the Thailand Science Research and Innovation Fund Chulalongkorn University (CU_FRB65_hea (59) 068_33_12) and the Second Century Fund (C2F), Chulalongkorn University.
Original Paper
Title of original paper: Optimization of Anti-TIM3 Chimeric Antigen Receptor with CD8α Spacer and TNFR-Based Costimulation for Enhanced Efficacy in AML Therapy
Journal: Biomedicine & Pharmacotherapy
DOI: 10.1016/j.biopha.2024.117388